<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031534</url>
  </required_header>
  <id_info>
    <org_study_id>CHB16.03</org_study_id>
    <nct_id>NCT04031534</nct_id>
  </id_info>
  <brief_title>Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma</brief_title>
  <acronym>HYPONECK</acronym>
  <official_title>Comparative Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma : Correlation With Immunohistochemistry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoxia imaging has not been studied extensively by combining PET and MRI data. Few studies
      performed the double imaging and none associated anatomopathology with it . This study will
      use a rigorous methodology through the production of PET/MRI images at the same time by
      transferring the patient directly from PET to MRI. In addition, the population, unlike other
      studies, will include preoperative patients with 24-hour surgery for hypoxia imaging by
      obtaining additional data through specific immunohistochemical analysis of hypoxia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of biodistribution of F-Miso PET scan in pre-therapeutic and sequences of MRI in patient with squamous cells carcinoma of oropharynx</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of F-Miso PET scan and Magnetic resonance imaging to measure hypoxia</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between recurrence free survival at one year and rate of hypoxia determined by the 3 techniques (PET scan, MRI and IHC)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Squamous Cell Carcinoma of the Oropharynx</condition>
  <arm_group>
    <arm_group_label>Measure of hypoxia by F-Miso PET scan and RMI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will undergo F-Miso PET scan and MRI to detect hypoxia. Imaging will be correlated with immunohistochemistry on tumour biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-Miso PET scan coupled with MRI</intervention_name>
    <description>Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy</description>
    <arm_group_label>Measure of hypoxia by F-Miso PET scan and RMI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with squamous cells carcinoma of oropharynx

          -  Age Superior to 10 years old

          -  Male or Female

          -  measurable target according RECIST criteria

        Exclusion Criteria:

          -  -Other histologic cancer than squamous cells carcinoma of oropharynx

          -  No measurable target

          -  Presence of metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastien Thureau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastien Thureau, MD, PhD</last_name>
    <phone>+33232082992</phone>
    <email>sebastien.thureau@chb.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doriane Richard, PhD</last_name>
    <phone>+33232082985</phone>
    <email>doriane.richard@chb.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Thureau, Md, PhD</last_name>
      <phone>+33232082992</phone>
      <email>sebastien.thureau@chb.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>F-Miso PET scan</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>immunohistochemistry</keyword>
  <keyword>Head and neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

